Literature DB >> 28508969

Five-year follow-up of a case of lipoprotein glomerulopathy with APOE Kyoto mutation.

Ryosuke Usui1, Masaki Takahashi2, Kosaku Nitta3, Minako Koike4.   

Abstract

We report the case of a 34-year-old Japanese male with lipoprotein glomerulopathy (LPG). Renal biopsy showed LPG, and followed by a genetic analysis revealed a mutation in apolipoprotein E gene (APOE Kyoto; Arg25Cys). We started treatment with probucol, bezafibrate, losartan, and allopurinol. Urinary protein decreased in response to treatment but has remained at about 1.27 ± 0.71 g/gCr, and a repeat biopsy which was performed 1 year after the first biopsy showed no clear evidence of pathological remission and complication of other glomerular disease. After 5 years of follow-up after the start of treatment, renal function has almost maintained without apparent deterioration. Interestingly, the course of the urinary protein level closely paralleled his triglyceride and cholesterol levels in a long-term. This observation suggests the importance of tight control of lipid profiles as a means of renoprotection in LPG patient.

Entities:  

Keywords:  APOE Kyoto; Lipoprotein glomerulopathy; Nephrotic syndrome

Year:  2016        PMID: 28508969      PMCID: PMC5411641          DOI: 10.1007/s13730-016-0214-5

Source DB:  PubMed          Journal:  CEN Case Rep        ISSN: 2192-4449


  28 in total

Review 1.  Impact of lipoprotein glomerulopathy on the relationship between lipids and renal diseases.

Authors:  Takao Saito; Akira Matsunaga; Shinichi Oikawa
Journal:  Am J Kidney Dis       Date:  2006-02       Impact factor: 8.860

Review 2.  A receptor-mediated pathway for cholesterol homeostasis.

Authors:  M S Brown; J L Goldstein
Journal:  Science       Date:  1986-04-04       Impact factor: 47.728

3.  A novel apolipoprotein E mutation, E2 (Arg25Cys), in lipoprotein glomerulopathy.

Authors:  A Matsunaga; J Sasaki; T Komatsu; K Kanatsu; E Tsuji; K Moriyama; T Koga; K Arakawa; S Oikawa; T Saito; T Kita; T Doi
Journal:  Kidney Int       Date:  1999-08       Impact factor: 10.612

4.  Successful treatment of lipoprotein glomerulopathy in a daughter and a mother using niceritrol.

Authors:  Hiroko Hamatani; Keiju Hiromura; Keiko Kobatake; Hiroaki Yoshida; Satsuki Kobayashi; Naohiro Yoneda; Ken Kayakabe; Takayuki Matsumoto; Takashi Kuroiwa; Kazue Ueki; Yoshihisa Nojima
Journal:  Clin Exp Nephrol       Date:  2010-09-15       Impact factor: 2.801

5.  Improvement of nephrotic syndrome by intensive lipid-lowering therapy in a patient with lipoprotein glomerulopathy.

Authors:  Akira Matsunaga; Masayuki Furuyama; Taeko Hashimoto; Kentaro Toyoda; Daisuke Ogino; Kiyoshi Hayasaka
Journal:  Clin Exp Nephrol       Date:  2009-07-15       Impact factor: 2.801

6.  Hypertriglyceridemia and lowered apolipoprotein C-II/C-III ratio in uremia: effect of a fibric acid, clinofibrate.

Authors:  Y Nishizawa; T Shoji; H Nishitani; M Yamakawa; T Konishi; K Kawasaki; H Morii
Journal:  Kidney Int       Date:  1993-12       Impact factor: 10.612

7.  A founder haplotype of APOE-Sendai mutation associated with lipoprotein glomerulopathy.

Authors:  Kentaro Toyota; Taeko Hashimoto; Daisuke Ogino; Akira Matsunaga; Minoru Ito; Ikuto Masakane; Noriyuki Degawa; Hiroshi Sato; Sayuri Shirai; Kazuo Umetsu; Gen Tamiya; Takao Saito; Kiyoshi Hayasaka
Journal:  J Hum Genet       Date:  2013-02-14       Impact factor: 3.172

8.  PPAR{alpha} attenuates the proinflammatory response in activated mesangial cells.

Authors:  Keiichi Kono; Yuji Kamijo; Kazuhiko Hora; Kyoko Takahashi; Makoto Higuchi; Kendo Kiyosawa; Hidekazu Shigematsu; Frank J Gonzalez; Toshifumi Aoyama
Journal:  Am J Physiol Renal Physiol       Date:  2008-11-26

9.  Lipoprotein glomerulopathy: glomerular lipoprotein thrombi in a patient with hyperlipoproteinemia.

Authors:  T Saito; H Sato; K Kudo; S Oikawa; T Shibata; Y Hara; K Yoshinaga; H Sakaguchi
Journal:  Am J Kidney Dis       Date:  1989-02       Impact factor: 8.860

10.  Resolution of typical lipoprotein glomerulopathy by intensive lipid-lowering therapy.

Authors:  Norio Ieiri; Osamu Hotta; Yoshio Taguma
Journal:  Am J Kidney Dis       Date:  2003-01       Impact factor: 8.860

View more
  3 in total

1.  Lipoprotein Glomerulopathy, First Case Report from Canada.

Authors:  Julie Anne Ting; Susanna A McRae; Daniel Schwartz; Sean J Barbour; Maziar Riazy
Journal:  Int J Nephrol Renovasc Dis       Date:  2022-06-21

Review 2.  An Updated Review and Meta Analysis of Lipoprotein Glomerulopathy.

Authors:  Meng-Shi Li; Yang Li; Yang Liu; Xu-Jie Zhou; Hong Zhang
Journal:  Front Med (Lausanne)       Date:  2022-05-06

Review 3.  Pathogenesis, histopathologic findings and treatment modalities of lipoprotein glomerulopathy: A review.

Authors:  Eduardo Cambruzzi; Karla Lais Pêgas
Journal:  J Bras Nefrol       Date:  2018-11-08
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.